This investigation formed part of a wider study into optics of the human eye in people with DM1. The study complied with the tenets of Declaration of Helsinki and was approved by the university's Human Research Ethics Committee. All participants gave informed consent.
This investigation comprised participants under 47 years of age. There were 43 participants (33 ± 8 years) with DM1 and 32 (34 ± 8 years) age-matched control participants. Details of participants are given in the
Table. There were no significant differences in the mean equivalent refractive error and visual acuity between the two groups.
Visual functions testing and ocular health assessment included case history, slit lamp biomicroscopy, fundus examination, intraocular pressure (I-Care, Tiolat Oy, Helsinki, Finland), and color vision assessment (Lanthony desaturated D15). Blood was collected from participants and analyzed for HbA1c levels.
Participants with corrected visual acuities ≥0.1 logMAR, Pelli-Robson contrast sensitivity scores ≥ 1.65, equivalent spherical refraction ≤ ±3.5 D, and normal color vision were included. Participants with mild diabetic retinopathy were also included, for example, microaneurysms, hard exudates, cotton-wool spots, and/or mild retinal hemorrhages. Some participants were recruited through the Longitudinal Assessment of Neuropathy in Diabetes using novel ophthalmic Markers (LANDMark) study at the Institute of Health and Biomedical Innovation,
17 in which the eye on the side of hand dominance was examined; as this testing involved contact with the cornea, we examined the other eye on the same day where possible. If this eye did not fulfill the criteria and the participant was able to return on another day, we tested the better eye. For participants recruited outside this study, the right eye was selected where it fulfilled the criteria; otherwise the left eye was selected.
Participants were excluded from the study if they demonstrated the following: moderate to severe diabetic retinopathy (e.g., soft exudates, venous bleeding, and/or severe retinal hemorrhage), retinal diseases, glaucoma, uveitis, ocular trauma or surgery, epilepsy, endocrine disorders (except diabetes), hypertension, neurologic or psychiatric disorders, anemia and cataract (posterior subcapsular cataract, cortical and nuclear of grades higher than 1). Slit lamp photographs and C-Quant values (straylight > 1.60 log[s] was excluded) were used to classify participants with and without cataract. Cataract was classified on the basis of the lens opacity classification system III. Participants using systemic medications with known accommodation effects or central nervous system effects were excluded.